MedTrace Logo

Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine

NCT05547802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122

Last updated 2022-09-21

No results posted yet for this study

Summary

In this prospective study, SARS-CoV-2 spike protein specific total immunoglobulin (Ig) levels are analyzed before and after BNT162b2 third mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in comparison to immunized participants with three doses of BNT162b2 vaccination. Questionnaires from recruited participants are reviewed prior to booster vaccination for the occurrence of a previous SARS-CoV-2 infection and hospitalization.

Conditions

  • Basic BBIBP-CorV Vaccination is Not as Effective as BNT162b

Interventions

BIOLOGICAL

BBIBP-CorV and/or BNT162b2 vaccine

Booster immunization was carried out at least 4 months after the first two doses of basic immunization.

Sponsors & Collaborators

  • University of Debrecen

    lead OTHER

Principal Investigators

  • Zoltán Szekanecz, MD, PhD · University of Debrecen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2022-01-06
Completion
2022-03-28

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05547802 on ClinicalTrials.gov